New dual inhibitor SGLT2/DPP-4 combination therapy offers improved glycemic control as an adjunct to diet and exercise
New GLYXAMBI savings program offered for eligible patients
First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies (NYSE:LLY)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.